Role of depression in blood pressure control. A cross-sectional multicentric study

Tunis Med. 2024 Jan 5;102(1):7-12. doi: 10.62438/tunismed.v102i1.4723.
[Article in French]

Abstract

Research problem: Hypertension is a multifactorial disease that affects approximately one third of the Tunisian adult population. It is a major risk factor for stroke and cardiovascular disease. Environmental and psychosocial factors play an important role in hypertension onset and control. The prevalence of depression among hypertensive patients is 26, 8% and its presence is associated with increased risk of cardiovascular related morbi-mortality. Our study aims to evaluate the role of depression in blood pressure control among ambulatory hypertensive patients. Investigative process: This study is a cross-sectional, multicentric and descriptive study. We intend to include three hundred and two patients. A 24-hour ambulatory blood pressure monitor will be used to evaluate blood pressure control. Depression will be assessed by the 9-item Patient Health Questionnaire (PHQ-9) in Tunisian dialect. Clinical, socio-environmental, psychosocial and therapeutic and prognosis data will be collected from medical records. Patients will be classified into two groups: Controlled versus non-controlled hypertension. PHQ-9 scores will be then compared between the two cohorts.

Research plan: Ethical considerations will be undertaken and respected. All patients should express an informed oral consent before enrollment. This trial will run for three months from the 15th August 2022.

Trial registration: NCT05516173.

Keywords: Ambulatory; Blood Pressure Monitoring; Patient Health Questionnaire; Tunisia; depression; hypertension.

Publication types

  • Multicenter Study
  • English Abstract

MeSH terms

  • Adult
  • Blood Pressure
  • Blood Pressure Monitoring, Ambulatory*
  • Cross-Sectional Studies
  • Depression / epidemiology
  • Humans
  • Hypertension* / complications
  • Hypertension* / epidemiology
  • Hypertension* / therapy

Associated data

  • ClinicalTrials.gov/NCT05516173